


Accelerating Transformative Opportunities

A GLOBAL CALL TO FIND, SUPPORT AND ACCELERATE DIABETES SOLUTIONS

The 2018 T1D Exchange Diabetes Innovation Challenge is an open, global competition to identify and accelerate transformational advancements in diagnostics, therapeutics, devices and solutions that aim to improve patient outcomes for those living with diabetes.

The goal of the Challenge is to identify the most promising innovations in diabetes, and present them to our network of funders, investors, and partners from academia and industry. Our aim is to help find these innovative organizations, raise their visibility and invite them to make connections that can ultimately lead to them securing the necessary support to advance to the next stage of development. The vision for the Diabetes Innovation Challenge is to accelerate translation and delivery of new therapies to the patient community.

JOIN OUR INNOVATIVE NETWORK




GET INVOLVED

Partner with T1D Exchange to spotlight your brand through a range of sponsorship opportunities:

- Participation & Roles In the Diabetes Innovation Challenge Award Process
- Branding & Marketing
- Additional Events, including the 2017 Annual Meeting

For more information, contact Challenge@T1DExchange.org or visit our site, bit.ly/T1DXinnovation2018

The Diabetes Innovation Challenge by the Numbers*



*Event statistics are from the 2016 Diabetes Innovation Challenge

2016 AWARD RECIPIENTS

EARLY-TO-PRECLINICAL STAGE PROJECTS

1st – Integrated Medical (Irvine, CA)

Fully-integrated, low cost, implantable, wireless, continuous glucose monitoring platform.

2nd – Glyscend (Baltimore, MD)

Orally-administered intestinal coating which mimics the therapeutic benefits of bariatric surgery on type 2 diabetes.

3rd – WindGap Medical (Somerville, MA)

Autoinjector that automates the rehydration and administration of lyophilized drugs, such as glucagon.

PEOPLE'S CHOICE

Sproutel (Providence, RI) The teddy bear teaching tool.

LATE-STAGE PROJECTS

(PRE-CLINICAL THROUGH TRANSLATIONAL)

1st – Enable Biosciences (San Francisco, CA)

Ultrasensitive non-radioactive autoantibody test that can be readily used for population screening.

2nd – AdmetSys (Boston, MA)

Artificial pancreas system specifically for the needs of diabetics in-hospital.

3rd – Polyphotonix (Durham, UK)

Non-invasive, low cost diabetic retinopathy mask that can be used by the patient in their own home while asleep.

2016 SPONSORS



T1D Exchange is a nonprofit founded on the belief that people affected by T1D need better solutions - treatments and care - faster. The organization places this community of people at the center of the work, offering researchers access to aggregated clinical, biological, patient-reported outcomes and electronic health record data. This model fosters collaboration among patients, physicians, researchers and industry, and drives innovation to tangibly improve outcomes for people with T1D.



T1D Exchange®